Abstract | BACKGROUND AND PURPOSE: METHODS: We investigated the relationship between plasma levels of 15-dPGJ2 and early neurological deterioration (END), infarct volume, and neurologic outcome in 552 patients with an acute stroke admitted within 24 hours after symptoms onset. RESULTS: Median [quartiles] plasma 15-dPGJ2 levels on admission were significantly higher in patients than in controls (60.5 [11.2 to 109.4] versus 5.0 [3.8 to 7.2] pg/mL; P<0.0001). Levels of this prostaglandin were also significantly higher in patients with vascular risk factors (history of hypertension or diabetes) and with atherothrombotic infarcts (113.9 [81.6 to 139.7] pg/mL), than in those with lacunar (58.7 [32.7 to 86.2] pg/mL), cardioembolic (12.1 [6.5 to 39.2] pg/mL), or undetermined origin infarcts (11.4 [5.6 to 24.3] pg/mL) (P<0.0001). In the subgroup of patients with atherothrombotic infarcts, the adjusted odds ratio of END and poor outcome for 1 pg/mL increase in 15-dPGJ2 were 0.95 (95% CI, 0.94 to 0.97) and 0.97 (95% CI, 0.96 to 0.98), respectively. In a generalized linear model, by 1 U increase in 15-dPGJ2, there was a reduction of 0.47 mL (95% CI, 0.32 to 0.63) in the mean estimated infarct volume. CONCLUSIONS: Increased plasma 15-dPGJ2 concentration is associated with good early and late neurological outcome and smaller infarct volume. These findings suggest a neuroprotective effect of 15-dPGJ2 in atherothrombotic ischemic stroke.
|
Authors | Miguel Blanco, María Angeles Moro, Antonio Dávalos, Rogelio Leira, Mar Castellanos, Joaquín Serena, José Vivancos, Manuel Rodríguez-Yáñez, Ignacio Lizasoain, José Castillo |
Journal | Stroke
(Stroke)
Vol. 36
Issue 6
Pg. 1189-94
(Jun 2005)
ISSN: 1524-4628 [Electronic] United States |
PMID | 15879329
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 15-deoxyprostaglandin J2
- Anti-Inflammatory Agents
- Ligands
- PPAR gamma
- Prostaglandin D2
|
Topics |
- Acute Disease
- Aged
- Anti-Inflammatory Agents
(pharmacology)
- Brain Ischemia
(pathology)
- Case-Control Studies
- Female
- Humans
- Inflammation
- Ligands
- Male
- Middle Aged
- Nervous System Diseases
(pathology)
- Odds Ratio
- PPAR gamma
(agonists, metabolism)
- Prostaglandin D2
(analogs & derivatives, blood)
- Regression Analysis
- Stroke
(blood, mortality, therapy)
- Thrombosis
(blood, mortality, therapy)
- Time Factors
- Treatment Outcome
|